WBDE(SZ:002082) Ge Long Hui·2025-12-12 13:11Core Viewpoint - Wanbangde (002082.SZ) announced the completion of participant enrollment for its Phase II/III clinical trial of the new drug Huperzine A controlled-release tablets for treating mild to moderate Alzheimer's disease [1] Group 1: Company Developments - Wanbangde's wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., has completed the enrollment of 50 subjects for the critical registration clinical trial [1] - Huperzine A is a cholinesterase inhibitor aimed at improving cognitive function [1] Group 2: Drug Potential - Preclinical studies have shown that Huperzine A has the potential to delay the progression of Alzheimer's disease and offers broad benefits, including the reduction of beta-amyloid protein, anti-inflammatory effects, antioxidant stress response, and neuroprotection [1] - The drug is expected to become a broad-spectrum treatment for Alzheimer's disease-related dementia [1]